J&J sees AI halving the time to generate drug development leads
By Michael Erman NEW YORK, April 27 (Reuters) - Johnson & Johnson is using artificial intelligence to slash by half the time it takes to generate new leads for developing drugs, the company's chief information officer said on Monday.